However, a ruthenium-derived glutathione transferase (GSTP-1) inhibitor, combined with olaparib, dramatically reduced the expression of the BRCA1 protein as well as the inhibition of BRCA1 replication in triple-negative BRCA1 wild-type MDA-MB-231 breast cancer cells [52]. Here, BRCA1 is linked to breast carcinoma.